Biovotion provides clinical-grade wearable solutions based on the company’s IP and know-how in non-invasive physiological monitoring, including vital sign, hydration, and glucose tracking. Its platform targets consumers and clinical users to support healthy lifestyles, improve healthcare treatment outcomes, and help reduce healthcare costs. The company says its offerings are grounded in clinical-grade measurement capabilities. Biovotion plans to use new funding to prepare the introduction of its platform into medical markets. The company was founded in 2011 by Dr. Andreas Caduff and is based in Zurich, Switzerland. Current financing activity indicates a push toward medical-market commercialization rather than a change in core product focus.

Total raised

$10M

Funding rounds

1

Latest round

Series A

Latest activity

Jun 2016